# Risk: __Enteric involvement in COVID-19 patients__ (PBN__Risk_292)

## Property: has_RiskSubject

* [hospitalized covid-19 patients](../Stakeholder/PBN__Stakeholder_1091)

## Property: has_RiskISO_Impact

* [Health and care](../RiskISO/PBN__RiskISO_Purpose_0)

## Property: has_RiskSource

* [lodder_sars-cov-2_2020](../Article/PBN__Article_70)

## Property: has_RiskName

Increased severity, complications in diagnosis and treatment

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskTechnology

* [gastrointestinal monitoring tools](../Technology/PBN__Technology_1001)
* [diagnostic tests](../Technology/PBN__Technology_1002)

## Property: has_RiskOwner

* [medical centers](../Stakeholder/PBN__Stakeholder_1092)
* [healthcare providers](../Stakeholder/PBN__Stakeholder_121)

## Property: has_RiskType

* [health](../RiskType/PBN__RiskType_4)

## Property: has_RiskDescription

Evidence of gastrointestinal symptoms and enteric involvement in COVID-19 patients.

## Property: has_RiskISO_Purpose

* [Resilience](../RiskISO/PBN__RiskISO_Impact_2)

## Property: has_RiskMitigation

* [Attention to liver transplant recipients with metabolic comorbidities](../RiskMitigation/PBN__RiskMitigation_365)
* [Monitor and manage gastrointestinal symptoms, enhance diagnostic capabilities](../RiskMitigation/PBN__RiskMitigation_2215)

